Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Firefly Neuroscience (AIFF) over the last 15 years, with Q3 2025 value amounting to -$13000.0.

  • Firefly Neuroscience's Change in Receivables fell 10928.57% to -$13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$84000.0, marking a year-over-year decrease of 14640.88%. This contributed to the annual value of $37000.0 for FY2024, which is 4307.69% down from last year.
  • Firefly Neuroscience's Change in Receivables amounted to -$13000.0 in Q3 2025, which was down 10928.57% from $52000.0 recorded in Q2 2025.
  • Firefly Neuroscience's Change in Receivables' 5-year high stood at $1.9 million during Q2 2022, with a 5-year trough of -$2.1 million in Q3 2022.
  • In the last 5 years, Firefly Neuroscience's Change in Receivables had a median value of $5811.5 in 2022 and averaged -$16896.8.
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 66570.21% in 2021, then soared by 530000.0% in 2025.
  • Quarter analysis of 5 years shows Firefly Neuroscience's Change in Receivables stood at -$1.2 million in 2021, then surged by 108.05% to $97385.0 in 2022, then plummeted by 56.87% to $42000.0 in 2023, then plummeted by 342.86% to -$102000.0 in 2024, then skyrocketed by 87.25% to -$13000.0 in 2025.
  • Its last three reported values are -$13000.0 in Q3 2025, $52000.0 for Q2 2025, and -$21000.0 during Q1 2025.